Condition: Phenylketonuria (PKU) · Sponsor: BioMarin Pharmaceutical
This is a 10-year multi-center, prospective, longitudinal, single arm study evaluating immunologic, inflammatory and laboratory parameters associated with long-term Palynziq treatment in subjects with phenylketonuria (PKU) in the United States (US). Subjects in the US for whom a clinical decision has been made that they will receive pegvaliase to treat their PKU within 30 days following the date of enrollment in Study 165-501 (incident-users) or who have previously started treatment with pegvaliase at the date of enrollment in Study 165-501 (prevalent-users) are eligible for participation in Study 165-503.
This description comes directly from the study's public registry record.
165-503 Program Director · 1-800-983-4587 · medinfo@bmrn.com
Medical Director, MD · 1-800-983-4587 · medinfo@bmrn.com
Always discuss trial participation with your own doctor first.
| University of Colorado | Aurora, Colorado, United States | Recruiting |
| Emory University | Atlanta, Georgia, United States | Recruiting |
| Northwestern University | Chicago, Illinois, United States | Recruiting |
| Riley Children's Hospital/ Indiana University Health | Indianapolis, Indiana, United States | Recruiting |
| Tulane University School of Medicine | New Orleans, Louisiana, United States | Recruiting |
| Boston Children's Hospital | Boston, Massachusetts, United States | Recruiting |
| Oregon Health & Science University | Portland, Oregon, United States | Recruiting |
| University of Pittsburgh Medical Center | Pittsburgh, Pennsylvania, United States | Recruiting |
| Vanderbilt University Medical School | Nashville, Tennessee, United States | Recruiting |
| UT Southwestern Medical Center | Dallas, Texas, United States | Recruiting |
| Children's Wisconsin/Medical College of Wisconsin | Milwaukee, Wisconsin, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06305234